Analysts Set Expectations for VNDA Q3 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a report released on Thursday, October 31st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will earn ($0.16) per share for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals' Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.48) EPS.

Several other analysts have also issued reports on the stock. Cantor Fitzgerald upped their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an "overweight" rating in a research report on Thursday, August 1st. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research report on Friday. They set a "hold" rating for the company.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA traded up $0.19 during trading on Monday, hitting $4.85. 781,658 shares of the company's stock traded hands, compared to its average volume of 1,316,204. The stock has a fifty day moving average of $4.83 and a two-hundred day moving average of $5.24. Vanda Pharmaceuticals has a 12-month low of $3.30 and a 12-month high of $6.75. The firm has a market cap of $282.71 million, a P/E ratio of -24.47 and a beta of 0.77.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors have recently modified their holdings of VNDA. China Universal Asset Management Co. Ltd. lifted its holdings in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 4,374 shares during the period. ORG Wealth Partners LLC purchased a new stake in Vanda Pharmaceuticals in the third quarter worth about $40,000. SG Americas Securities LLC lifted its holdings in Vanda Pharmaceuticals by 88.5% in the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 9,580 shares during the period. Nantahala Capital Management LLC lifted its holdings in Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company's stock worth $9,003,000 after buying an additional 580,265 shares during the period. Finally, Susquehanna Fundamental Investments LLC lifted its holdings in Vanda Pharmaceuticals by 2.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company's stock worth $1,625,000 after buying an additional 5,994 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.